Evoke Pharma (NASDAQ:EVOK) Now Covered by StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a report released on Tuesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Up 2.2 %

Shares of EVOK opened at $2.75 on Tuesday. Evoke Pharma has a 12-month low of $1.94 and a 12-month high of $12.32. The business’s fifty day moving average is $3.02 and its 200 day moving average is $4.21. The stock has a market cap of $4.11 million, a P/E ratio of -0.25 and a beta of 0.30.

Evoke Pharma (NASDAQ:EVOK) last issued its earnings results on Thursday, March 13th. The specialty pharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.24). Evoke Pharma had a negative return on equity of 308.49% and a negative net margin of 71.32%. The firm had revenue of $3.31 million during the quarter, compared to the consensus estimate of $3.08 million.

Hedge Funds Weigh In On Evoke Pharma

A hedge fund recently raised its stake in Evoke Pharma stock. Nantahala Capital Management LLC raised its stake in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) by 163.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 148,194 shares of the specialty pharmaceutical company’s stock after acquiring an additional 91,945 shares during the period. Nantahala Capital Management LLC owned about 9.95% of Evoke Pharma worth $655,000 as of its most recent SEC filing.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.